RECRUITING
I'm interested ...!!
Nasal Antisepsis for C. Auris Prevention
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Conditions:
🦠 Candida Auris Infection 🦠 Colonization, Asymptomatic
🗓️ Study Start (Actual) 29 January 2024
🗓️ Primary Completion (Estimated) December 2026
✅ Study Completion (Estimated) December 2028
👥 Enrollment (Estimated) 120
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 Chicago, Illinois, United States
📍 Chicago, Illinois, United States
📍 Hinsdale, Illinois, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * History of C. auris colonization or infection
    • * Patient in a participating facility

    Exclusion Criteria:

    • * History of severe allergy to iodine-based products, defined as anaphylaxis or rash
    • * Currently breastfeeding or pregnant
    • * Non-English language speaking
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 8 February 2024
  • First Submitted that Met QC Criteria 20 February 2024
  • First Posted 28 February 2024

Study Record Updates

  • Last Update Submitted that Met QC Criteria 20 February 2024
  • Last Update Posted 28 February 2024
  • Last Verified February 2024
I'm interested ...!!